Developing effective cancer vaccines

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Baxevanis, Constantin N ^a   Perez, Sonia A ^a   Papamichail, Michael ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; E 75 VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; PROST VAC; PROVENGE; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; VITESPEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATE RESISTANT PROSTATE CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; DENDRITIC CELL; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; FOLLOW UP; HUMAN PAPILLOMAVIRUS TYPE 16; MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION;

CANCER VACCINES; CHEMISTRY, PHARMACEUTICAL; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 80053222721     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70205-2     Document Type: Article

References (9)

1. PW Kantoff, CS Higano, ND Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl JMed 363 2010 411 422
2. PW Kantoff, TJ Schuetz, BA Blumenstein et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
3. SA Perez, E von Hofe, NL Kallinteris et al. A new era in anticancer peptide vaccines Cancer 116 2010 2071 2080
4. JP Holmes, LC Benavides, JD Gates et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine J Clin Oncol 26 2008 3426 3433
5. SA Perez, NL Kallinteris, S Bisias et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer Clin Cancer Res 16 2010 3495 3506
6. GG Kenter, MJ Welters, AR Valentijn et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N Engl JMed 361 2009 1838 1847
7. CA Uyl-de Groot, JB Vermorken, MG Hanna Jr et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits Vaccine 23 2005 2379 2387 (Pubitemid 40341488)
8. A Testori, J Richards, E Whitman et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group J Clin Oncol 26 2008 955 962 (Pubitemid 351398090)
9. C Wood, P Srivastava, R Bukowski et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 2008 145 154